Ibio stock analysis
Want to see IBIO full AI Analyst Report?
Ibio (IBIO) Stock Price & Analysis
IBIO Stock Chart & Stats
- Day’s Range
- $0.75 - $0.87
- 52-Week Range
- $0.68 - $3.82
- Previous Close
- $0.75
- Volume
- N/A
- Average Volume (3M)
- 610.06K
- Market Cap
- $52.71M
- Enterprise Value
- $104.27M
- Total Cash (Recent Filing)
- $76.65M
- Total Debt (Recent Filing)
- $2.07M
- Price to Earnings (P/E)
- ―
- Beta
- 1.07
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- -0.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Differentiation
The extended primate results support a potentially differentiated obesity therapy focused on fat-selective weight loss and lean-mass preservation. If later studies reproduce these effects, IBIO-610 could address an important limitation of existing treatments and strengthen iBio’s strategic position.
Revenue Rebound
The sharp TTM revenue rebound indicates improving commercial or partnership-related activity from a very small base. Although the scale remains limited, continued top-line expansion could provide a broader funding foundation and demonstrate progress beyond a purely research-stage operating profile.
Low Leverage
Very low leverage gives iBio more financial flexibility than a highly indebted biotechnology company. Limited debt obligations reduce pressure from interest and refinancing requirements, leaving management greater capacity to direct available resources toward pipeline development and future milestones.
Bears Say
Persistent Large Losses
The company has not yet demonstrated a sustainable profit model, and its losses remain extremely large relative to revenue. Persistent negative earnings can erode equity over time, constrain strategic flexibility, and increase dependence on external financing while products remain under development.
Continued Cash Burn
Negative operating and free cash flow show that iBio is not currently self-funding its operations. Continued cash consumption can require additional financing before the pipeline generates meaningful revenue, increasing pressure on capital allocation and potentially limiting development choices.
Preclinical Development Stage
The key pipeline assets have generated encouraging animal and laboratory findings but have not yet established human safety or efficacy. Their value therefore remains dependent on future clinical execution, regulatory progress, and the ability to translate preclinical results into viable therapies.
Ibio News
IBIO FAQ
What was Ibio’s price range in the past 12 months?
What is Ibio’s market cap?
When is Ibio’s upcoming earnings report date?
How were Ibio’s earnings last quarter?
Is Ibio overvalued?
Does Ibio pay dividends?
What is Ibio’s EPS estimate?
How many shares outstanding does Ibio have?
What happened to Ibio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ibio?
What is the TipRanks Smart Score and how is it calculated?
Ibio Stock Smart Score
Company Description
Ibio
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Brenner
- Employees
- 23
- Website
- www.ibioinc.com
- Address
- 11750 Sorrento Valley Road, San Diego, CA, 92121, US
Ibio (IBIO) Earnings & Revenues
IBIO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 6 | 0 | 6 |










